Imagine being born without the body's 'training camp' for immune cells, leaving you defenseless against germs. Instead of relying on a rare and risky donor organ, this technology uses a patient's own skin or blood cells to grow a miniature, custom-made thymus in a lab. This tiny organ is then implanted to teach the body how to fight infections naturally.
Children born without a thymus face a 30% mortality rate from current transplants and a treatment cost exceeding €2.5 million. There is a critical lack of safe, affordable, and accessible immune system regeneration options.
A method to create patient-specific thymus organoids using induced pluripotent stem cells (iPSCs) and specific growth factors.
If you are a pharma company dealing with the high failure rates of donor transplants — this project developed a gene-modified cell therapy that creates patient-specific tissue. This reduces the 30% mortality rate associated with traditional thymus transplants.
If you are a clinic dealing with the lack of accessible thymus tissue for rare diseases — this project developed iPSC-derived organoids. This allows for a minimally invasive implant using the patient's own cells.
If you are a center dealing with AML patients who lost thymus function after high-dose chemotherapy — this project developed a regenerative therapy to restore immune function. This expands the market beyond rare congenital diseases to thousands of chemotherapy patients.
Current commercial products based on thymus tissue transplantation cost over €2.5 million per patient.
The strategy involves rapid market entry through Orphan Drug Designation for complete DiGeorge syndrome, followed by expansion into AML patient markets.
Based on available project data, the coordinator GENEWITY BV is accelerating pre-clinical development to enter the EU market with a pharma partner by 2028.
The project is pursuing Orphan Drug Designation to accelerate the pathway to clinical trials and market entry.
The goal is to enter the EU market with a pharmaceutical partner by 2028.
The project is driven by a lean, 100% industry-led consortium consisting of 2 SMEs based in the Netherlands. This structure suggests a high focus on commercial agility and direct path-to-market, avoiding the slower pace of academic-heavy partnerships.
Contact GENEWITY BV in the Netherlands
Contact us to explore licensing opportunities for iPSC-derived thymic organoids.
